Lusine Yaghjyan1, Eric McLaughlin2, Amy Lehman2, Marian L Neuhouser3, Thomas Rohan4, Dorothy S Lane5, Linda Snetselaar6, Electra Paskett7. 1. Department of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of Florida, 2004 Mowry Rd., Gainesville, FL, 32610, USA. lyaghjyan@ufl.edu. 2. Center for Biostatistics, Ohio State University, Columbus, OH, USA. 3. Public Health Sciences Division, Fred Hutch Cancer Center, Seattle, WA, USA. 4. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA. 5. Department of Family, Population and Preventive Medicine, Renaissance School of Medicine, Stony Brook University, New York, NY, USA. 6. Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, USA. 7. Division of Epidemiology, College of Public Health, Ohio State University, Columbus, OH, USA.
Abstract
PURPOSE: We investigated the association of coffee and caffeine with breast cancer (BCa) risk, overall and by ER/PR status. We also examined potential interactions of coffee and caffeine with postmenopausal hormone use. METHODS: Our study included 77,688 postmenopausal participants from the Women's Health Initiative observational study cohort without a history of any cancer at baseline (except non-melanoma skin) and with valid Food Frequency Questionnaire data and complete data on dietary caffeine. Regular coffee (none, 1, 2-3, 4-5, and ≥ 6 cups/day) and caffeine (tertiles) were assessed at baseline. Information on BCa risk factors was collected at baseline. The associations were examined using survival analysis, accounting for death as a competing risk. RESULTS: The median follow-up time for our cohort was 18.3 years. During the follow-up, 5005 women developed invasive breast cancer. In multivariable analysis, coffee was not associated with the overall invasive BCa risk. Higher caffeine intake was mildly associated with increased BCa risk (2nd vs. 1st tertile SHR = 1.10, 95% CI 1.03-1.18, 3rd vs. 1st tertile SHR-1.05, 95% CI 0.98-1.13, overall p = 0.03). We found no interaction of coffee/caffeine with postmenopausal hormone use (p interaction = 0.44 and 0.42, respectively). In the exploratory analysis by ER/PR status, we found a positive association of caffeine with ER+ /PR+ BCa (2nd vs. 1st tertile SHR = 1.17, 95% CI 1.07-1.28, 3rd vs. 1st tertile SHR = 1.13, 95% CI 1.03-1.24, overall p = 0.002); no associations were observed for ER-/PR- tumors. Coffee was not associated with the risk of ER+ /PR+ or ER-/PR- tumors. CONCLUSION: We found no associations of coffee with BCa risk, overall and for ER/PR-defined tumor subtypes. The higher caffeine consumption was mildly and positively associated with the overall BCa risk and with ER+ /PR+ tumors.
PURPOSE: We investigated the association of coffee and caffeine with breast cancer (BCa) risk, overall and by ER/PR status. We also examined potential interactions of coffee and caffeine with postmenopausal hormone use. METHODS: Our study included 77,688 postmenopausal participants from the Women's Health Initiative observational study cohort without a history of any cancer at baseline (except non-melanoma skin) and with valid Food Frequency Questionnaire data and complete data on dietary caffeine. Regular coffee (none, 1, 2-3, 4-5, and ≥ 6 cups/day) and caffeine (tertiles) were assessed at baseline. Information on BCa risk factors was collected at baseline. The associations were examined using survival analysis, accounting for death as a competing risk. RESULTS: The median follow-up time for our cohort was 18.3 years. During the follow-up, 5005 women developed invasive breast cancer. In multivariable analysis, coffee was not associated with the overall invasive BCa risk. Higher caffeine intake was mildly associated with increased BCa risk (2nd vs. 1st tertile SHR = 1.10, 95% CI 1.03-1.18, 3rd vs. 1st tertile SHR-1.05, 95% CI 0.98-1.13, overall p = 0.03). We found no interaction of coffee/caffeine with postmenopausal hormone use (p interaction = 0.44 and 0.42, respectively). In the exploratory analysis by ER/PR status, we found a positive association of caffeine with ER+ /PR+ BCa (2nd vs. 1st tertile SHR = 1.17, 95% CI 1.07-1.28, 3rd vs. 1st tertile SHR = 1.13, 95% CI 1.03-1.24, overall p = 0.002); no associations were observed for ER-/PR- tumors. Coffee was not associated with the risk of ER+ /PR+ or ER-/PR- tumors. CONCLUSION: We found no associations of coffee with BCa risk, overall and for ER/PR-defined tumor subtypes. The higher caffeine consumption was mildly and positively associated with the overall BCa risk and with ER+ /PR+ tumors.
Authors: Bente L Halvorsen; Monica H Carlsen; Katherine M Phillips; Siv K Bøhn; Kari Holte; David R Jacobs; Rune Blomhoff Journal: Am J Clin Nutr Date: 2006-07 Impact factor: 7.045
Authors: Julie A Baker; Gregory P Beehler; Abhishek C Sawant; Vijayvel Jayaprakash; Susan E McCann; Kirsten B Moysich Journal: J Nutr Date: 2006-01 Impact factor: 4.798
Authors: Julia S Sisti; Susan E Hankinson; Neil E Caporaso; Fangyi Gu; Rulla M Tamimi; Bernard Rosner; Xia Xu; Regina Ziegler; A Heather Eliassen Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-06-10 Impact factor: 4.254
Authors: Jin-Kyoung Oh; Sven Sandin; Peter Ström; Marie Löf; Hans-Olov Adami; Elisabete Weiderpass Journal: Int J Cancer Date: 2015-04-30 Impact factor: 7.396
Authors: P G Toniolo; M Levitz; A Zeleniuch-Jacquotte; S Banerjee; K L Koenig; R E Shore; P Strax; B S Pasternack Journal: J Natl Cancer Inst Date: 1995-02-01 Impact factor: 13.506
Authors: Elizabeth C Lowcock; Michelle Cotterchio; Laura N Anderson; Beatrice A Boucher; Ahmed El-Sohemy Journal: Nutr Cancer Date: 2013 Impact factor: 2.900
Authors: Joanne Kotsopoulos; A Heather Eliassen; Stacey A Missmer; Susan E Hankinson; Shelley S Tworoger Journal: Cancer Date: 2009-06-15 Impact factor: 6.860
Authors: Nirmala Bhoo-Pathy; Petra H M Peeters; Cuno S P M Uiterwaal; H Bas Bueno-de-Mesquita; Awang M Bulgiba; Bodil Hammer Bech; Kim Overvad; Anne Tjønneland; Anja Olsen; Françoise Clavel-Chapelon; Guy Fagherazzi; Florence Perquier; Birgit Teucher; Rudolf Kaaks; Madlen Schütze; Heiner Boeing; Pagona Lagiou; Philippos Orfanos; Antonia Trichopoulou; Claudia Agnoli; Amalia Mattiello; Domenico Palli; Rosario Tumino; Carlotta Sacerdote; Franzel J B van Duijnhoven; Tonje Braaten; Eiliv Lund; Guri Skeie; María-Luisa Redondo; Genevieve Buckland; Maria José Sánchez Pérez; Maria-Dolores Chirlaque; Eva Ardanaz; Pilar Amiano; Elisabet Wirfält; Peter Wallström; Ingegerd Johansson; Lena Maria Nilsson; Kay-Tee Khaw; Nick Wareham; Naomi E Allen; Timothy J Key; Sabina Rinaldi; Isabelle Romieu; Valentina Gallo; Elio Riboli; Carla H van Gils Journal: Breast Cancer Res Date: 2015-01-31 Impact factor: 6.466